Kepler Capital Markets reissued their buy rating on shares of Shire PLC (LON:SHP) in a research note published on Wednesday morning. They currently have a GBX 4,600 ($60.70) price objective on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on SHP. HSBC Holdings plc raised Shire PLC to a hold rating and set a GBX 4,450 ($58.72) price objective for the company in a research report on Thursday, July 6th. Royal Bank Of Canada reissued an outperform rating on shares of Shire PLC in a research note on Friday, July 7th. Liberum Capital reissued a hold rating and set a GBX 4,900 ($64.66) target price on shares of Shire PLC in a research note on Monday, July 10th. J P Morgan Chase & Co reissued an overweight rating and set a GBX 6,000 ($79.18) target price on shares of Shire PLC in a research note on Tuesday, July 11th. Finally, Societe Generale reissued a buy rating and set a GBX 7,500 ($98.97) target price on shares of Shire PLC in a research note on Wednesday, July 12th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of GBX 5,509.68 ($72.71).
TRADEMARK VIOLATION NOTICE: “Shire PLC (SHP) Receives Buy Rating from Kepler Capital Markets” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/02/shire-plc-shp-receives-buy-rating-from-kepler-capital-markets.html.
In related news, insider Anne Minto bought 190 shares of the stock in a transaction on Friday, September 29th. The shares were purchased at an average price of GBX 3,785 ($49.95) per share, for a total transaction of £7,191.50 ($9,489.97). Also, insider Flemming Ornskov bought 8,400 shares of the stock in a transaction on Tuesday, August 22nd. The shares were bought at an average price of GBX 3,665 ($48.36) per share, for a total transaction of £307,860 ($406,254.95).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.